Chia Tai Tianqing Pharmaceutical - PharmaKB

Company Reports

Company Reports

Disease Reports

Disease Reports

Company ReportsChia Tai Tianqing Pharmaceutical

Chia Tai Tianqing Pharmaceutical

Download report

Favorite

Financial

Marketed Drugs

Clinical Trials

Financial

Stock price

No data

Company Revenue

No data

Revenue by Drug

Marketed Drugs

Therapeutic Areas:

All

Classification:

All

Include Generics:

Trade Name	Drug Name	Approved	Patent Expires	Indication
Fosaprepitant dimeglumine	Fosaprepitant dimeglumine	2021-03-03		—
Fulvestrant	Fulvestrant	2020-02-07	2034	Breast neoplasms

Clinical Trials

Therapeutic Areas:

All

Classification:

All

Approval:

All

Status:

All

Phases:

All

Drug Name

Phase 1

Phase 2

Phase 3

Phase 4

Indication

,

,

breast neoplasms

,

triple negative breast neoplasms

,

breast neoplasms

,

Eribulin mesylate

,

breast neoplasms

,

Mycophenolate sodium

hyperlipoproteinemia type i

chronic renal insufficiency

,

,

kidney diseases

,

Mycophenolic acid

hyperlipoproteinemia type i

colorectal neoplasms

,

colonic neoplasms

,

,

,

iron-deficiency anemia

,

iron deficiencies

,

hepatocellular carcinoma

,

liver neoplasms

squamous cell carcinoma

,

colorectal neoplasms

,

stomach neoplasms

,

pancreatic neoplasms

,

esophageal squamous cell carcinoma

,

squamous cell carcinoma of head and neck

,

large b-cell lymphoma diffuse

,

gastrointestinal neoplasms

,

digestive system neoplasms

,

thyroid neoplasms

,

breast neoplasms

,

,

rectal neoplasms

,

b-cell lymphoma

,

pheochromocytoma

,

urologic neoplasms

,

gastrointestinal stromal tumors

,

neuroendocrine tumors

,

small cell lung carcinoma

,

female genital neoplasms

,

,

uterine cervical neoplasms

,

neoplasms by histologic type

,

triple negative breast neoplasms

,

male breast neoplasms

,

essential tremor

,

head and neck neoplasms

,

,

gastrointestinal diseases

,

digestive system diseases

,

,

,

,

,

esophageal neoplasms

,

neoplasm metastasis

,

,

,

,

,

nasopharyngeal carcinoma

,

hepatocellular carcinoma

,

nasopharyngeal neoplasms

,

liver neoplasms

,

hodgkin disease

,

squamous cell neoplasms

,

,

hypersensitivity

,

non-small-cell lung carcinoma

,

urinary bladder neoplasms

,

transitional cell carcinoma

,

small cell carcinoma

,

thyroid diseases

healthy volunteers/patients

,

pharmacokinetics

,

type 2 diabetes mellitus

,

diabetes mellitus

,

,

systemic scleroderma

,

diffuse scleroderma

,

,

non-alcoholic fatty liver disease

,

,

parkinson disease

,

shy-drager syndrome

,

multiple system atrophy

,

lewy body disease

,

,

synucleinopathies

,

progressive supranuclear palsy

,

corticobasal degeneration

Efbemalenograstim alfa

non-small-cell lung carcinoma

,

,

febrile neutropenia

,

colorectal neoplasms

,

pancreatic neoplasms

,

ovarian neoplasms

,

uterine cervical neoplasms

,

,

breast neoplasms

,

Aglatimagene besadenovec

,

triple negative breast neoplasms

,

pharmacokinetics

,

healthy volunteers/patients

,

pharmacological phenomena

,

,

breast neoplasms

,

,

neoplasm metastasis

,

,

ovarian neoplasms

,

non-small-cell lung carcinoma

,

pancreatic neoplasms

,

colorectal neoplasms

,

,

uterine cervical neoplasms

,

endometrial neoplasms

,

stomach neoplasms

,

urinary bladder neoplasms

,

small cell lung carcinoma

,

biliary tract neoplasms

,

,

,

hereditary breast and ovarian cancer syndrome

,

,

head and neck neoplasms

,

dna repair-deficiency disorders

,

,

ovarian epithelial carcinoma

,

,

hypersensitivity

,

,

prostatic neoplasms

,

castration-resistant prostatic neoplasms

,

,

coronary disease

,

coronary artery disease

,

myocardial ischemia

,

,

,

,

disease susceptibility

,

hepatocellular carcinoma

,

liver neoplasms

1

2

3

4

5

6

>

© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use